Related references
Note: Only part of the references are listed.TAS-102, a novel antitumor agent: A review of the mechanism of action
Heinz-Josef Lenz et al.
CANCER TREATMENT REVIEWS (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Peter M. Wilson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
Nozomu Tanaka et al.
ONCOLOGY REPORTS (2014)
Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
T. Doi et al.
BRITISH JOURNAL OF CANCER (2012)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino et al.
LANCET ONCOLOGY (2012)
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
Michael J. Overman et al.
INVESTIGATIONAL NEW DRUGS (2008)
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors
David S. Hong et al.
CANCER (2006)
Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides
M Fukushima et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
